Can a tweaked herpes virus help fight cancer? early trial underway

NCT ID NCT04735978

Ongoing Disease control Sponsor: Replimune, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a genetically modified herpes virus called RP3, alone or combined with the immunotherapy drug nivolumab, in 123 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the best dose. Participants must have a tumor that can be measured and agree to biopsies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RP3 (a genetically modified herpes simplex virus) and nivolumab (an immunotherapy drug)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This is a very early Phase 1 trial focused on safety and dosing, not yet on effectiveness. The virus and drug combination may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

Churchill Hospital

Oxford, OX3 9DU, United Kingdom
Hospital Clinic Barcelona

Barcelona, 08036, Spain
Hospital Clinico Universitario de Valencia

Valencia, 46010, Spain
Laboratoire de Recherche Translationnelle en Immunotherapie (LRTI), Gustave Roussy

Villejuif, 94805, France
MD Anderson Cancer Center

Houston, Texas, 77030, United States
START Madrid CIO Clara Campal, Hospital Universitario HM Sanchinarro Unidad de Ensayos Fase I Panta 3

Madrid, 28050, Spain
The Clatterbridge Cancer Centre NHS Foundation Trust

Bebington, Merseyside, CH63 4JY, United Kingdom
The Royal Marsden NHS Foundation Trust

London, SW3 6JJ, United Kingdom
UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania, 15232, United States
University General Hospital Attikon

Athens, 12462, Greece
University of Athens

Athens, 11527, Greece
University of Iowa

Iowa City, Iowa, 52242, United States
Vall d'Hebron Hospital Hospital Universitario Vall d´Hebron (Vall d'Hebron University Hospital)

Barcelona, 08035, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.